MX429166B - Uso de colageno-polivinilpirrolidona en la inflamacion y fibrosis pulmonar en pacientes infectados por el virus sars-cov2 (covid-19) - Google Patents

Uso de colageno-polivinilpirrolidona en la inflamacion y fibrosis pulmonar en pacientes infectados por el virus sars-cov2 (covid-19)

Info

Publication number
MX429166B
MX429166B MX2020008473A MX2020008473A MX429166B MX 429166 B MX429166 B MX 429166B MX 2020008473 A MX2020008473 A MX 2020008473A MX 2020008473 A MX2020008473 A MX 2020008473A MX 429166 B MX429166 B MX 429166B
Authority
MX
Mexico
Prior art keywords
covid
days
hours
collagen
sars
Prior art date
Application number
MX2020008473A
Other languages
English (en)
Other versions
MX2020008473A (es
Inventor
Carballeda Guadalupe Janette Furuzawa
Original Assignee
Aspid S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aspid S A De C V filed Critical Aspid S A De C V
Priority to MX2020008473A priority Critical patent/MX429166B/es
Priority to PE2023000269A priority patent/PE20231052A1/es
Priority to CA3189167A priority patent/CA3189167A1/en
Priority to CN202180064443.5A priority patent/CN116406300A/zh
Priority to BR112023002614A priority patent/BR112023002614A2/pt
Priority to EP21856312.0A priority patent/EP4197553A4/en
Priority to PCT/MX2021/050045 priority patent/WO2022035306A2/es
Priority to US18/021,141 priority patent/US20230285516A1/en
Publication of MX2020008473A publication Critical patent/MX2020008473A/es
Priority to CL2023000422A priority patent/CL2023000422A1/es
Publication of MX429166B publication Critical patent/MX429166B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con el uso decolágena polimerizada tipo I en pacientes Covid-19 positivos y a un régimen de dosificación por vía intramuscular cada 12 h durante 3 días y después cada 24 h durante 4 días en pacientes con enfermedad leve a moderada por Covid-19 o bien, a un régimen de dosificación por vía intramuscular cada 12 h durante 7 días en pacientes con enfermedad grave a semi-crítica por Covid-19. Además, se analizó la evolución clínica de cada paciente individualmente (Figuras 13 a 17 y 20 a 21) y de manera grupal(Figuras 18 y 19), tomando en cuenta los siguientes parámetros: porcentaje de SpO2, temperatura, frecuencia cardiaca, frecuencia respiratoria, intervalos de tos, dolor torácico, cefalea, disnea, odinofagia, anosmia, la pérdida del sentido del gusto, la presencia artralgias y mialgias y se documentó una mejoría clínica en todos los casos.
MX2020008473A 2020-08-12 2020-08-12 Uso de colageno-polivinilpirrolidona en la inflamacion y fibrosis pulmonar en pacientes infectados por el virus sars-cov2 (covid-19) MX429166B (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2020008473A MX429166B (es) 2020-08-12 2020-08-12 Uso de colageno-polivinilpirrolidona en la inflamacion y fibrosis pulmonar en pacientes infectados por el virus sars-cov2 (covid-19)
PE2023000269A PE20231052A1 (es) 2020-08-12 2021-08-11 Uso de colageno-polivinilpirrolidona en la inflamacion y fibrosis pulmonar en pacientes infectados por el virus sars-cov2 (covid-19)
CA3189167A CA3189167A1 (en) 2020-08-12 2021-08-11 Use of collagen-polyvinylpyrrolidone in pulmonary inflammation and fibrosis in patients infected by the sars-cov2 virus (covid-19)
CN202180064443.5A CN116406300A (zh) 2020-08-12 2021-08-11 胶原蛋白-聚乙烯吡咯烷酮在由SARS-CoV2病毒(Covid-19)感染的患者肺部炎症和纤维化中的用途
BR112023002614A BR112023002614A2 (pt) 2020-08-12 2021-08-11 Uso de colágeno-polivinilpirrolidona na inflamação e fibrose pulmonar em pacientes infectados pelo vírus sars-cov2 (covid-19)
EP21856312.0A EP4197553A4 (en) 2020-08-12 2021-08-11 USE OF COLLAGENO-POLYVINYLPYRROLIDONE AGAINST INFLAMMATION AND PULMONARY FIBROSIS IN PATIENTS INFECTED BY THE SARS-COV-2 VIRUS (COVID-19)
PCT/MX2021/050045 WO2022035306A2 (es) 2020-08-12 2021-08-11 Uso de colágeno-polivinilpirrolidona en la inflamación y fibrosis pulmonar en pacientes infectados por el virus sars-cov2 (covid-19)
US18/021,141 US20230285516A1 (en) 2020-08-12 2021-08-11 Use of collagen-polyvinylpyrrolidone in pulmonary inflammation and fibrosis in patients infected by the sars-cov2 virus (covid-19)
CL2023000422A CL2023000422A1 (es) 2020-08-12 2023-02-10 Uso de colágeno polimerizado para la inflamación y fibrosis pulmonar en pacientes infectados por sars-cov2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2020008473A MX429166B (es) 2020-08-12 2020-08-12 Uso de colageno-polivinilpirrolidona en la inflamacion y fibrosis pulmonar en pacientes infectados por el virus sars-cov2 (covid-19)

Publications (2)

Publication Number Publication Date
MX2020008473A MX2020008473A (es) 2022-02-14
MX429166B true MX429166B (es) 2025-11-13

Family

ID=80247247

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008473A MX429166B (es) 2020-08-12 2020-08-12 Uso de colageno-polivinilpirrolidona en la inflamacion y fibrosis pulmonar en pacientes infectados por el virus sars-cov2 (covid-19)

Country Status (9)

Country Link
US (1) US20230285516A1 (es)
EP (1) EP4197553A4 (es)
CN (1) CN116406300A (es)
BR (1) BR112023002614A2 (es)
CA (1) CA3189167A1 (es)
CL (1) CL2023000422A1 (es)
MX (1) MX429166B (es)
PE (1) PE20231052A1 (es)
WO (1) WO2022035306A2 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005080A (es) * 2004-05-27 2005-11-30 Aspid S A De C V Una composicion moduladora de la inflamacion articular cronica a base de colagena-polivinilpirrolidona.
CA2710380A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions
US20200237815A1 (en) * 2017-02-24 2020-07-30 Alain Martin Methods for treatment of lung damage and for inhibition of lung fibrosis
WO2021229577A1 (en) * 2020-05-12 2021-11-18 Collplant Ltd. Collagen as a delivery tool for metal-based anti-viral agents

Also Published As

Publication number Publication date
MX2020008473A (es) 2022-02-14
WO2022035306A2 (es) 2022-02-17
WO2022035306A3 (es) 2022-04-28
CA3189167A1 (en) 2022-02-17
CN116406300A (zh) 2023-07-07
EP4197553A4 (en) 2024-11-13
PE20231052A1 (es) 2023-07-11
CL2023000422A1 (es) 2023-09-15
US20230285516A1 (en) 2023-09-14
EP4197553A2 (en) 2023-06-21
BR112023002614A2 (pt) 2023-05-09